A significant and progressive decline in blood levels of omega-3 DHA transporter MFSD2a may be a biomarker of Alzheimer's disease
www.mdpi.com
From the publication:
The aim of this study was to investigate the expression of MFSD2a in the whole blood and brain as a potential biomarker of Alzheimer’s disease (AD). […] We found a significant and progressive decline of MFSD2a levels in blood of AD patients. We also corroborated a significant reduction of DHA and other n-3 long-chain polyunsaturated FA in serum of AD.